BLEXTEN 2.5 MG
BILASTINE : 2.5 MG · DIN 02519011 · ARALEZ PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is BLEXTEN?
BLEXTEN 2.5 MG contains BILASTINE : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02519011, held by ARALEZ PHARMACEUTICALS CANADA INC, supplied as SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BLEXTEN used for?
Symptomatic relief of seasonal allergic rhinitis (SAR) and chronic spontaneous urticaria (CSU) in patients 4 years of age and older with a body weight of at least 16 kg.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02519011 |
|---|---|
| Brand name | BLEXTEN |
| Generic / active ingredient | BILASTINE : 2.5 MG |
| Manufacturer | ARALEZ PHARMACEUTICALS CANADA INC |
| Strength | 2.5 MG |
| Dosage form | SOLUTION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | R06AX29 BILASTINE |
| AHFS class | 04:08.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Feb-2022 |
| Original market date | 2022-02-10 00:00:00 |
How is it administered?
4-11 years (>=16kg): 10 mg once daily. >=12 years: 20 mg once daily. Take on an empty stomach 1 hour before or 2 hours after food or fruit juice.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (Section 11 header present but content truncated).
How is it supplied?
10 mg orodispersible tablets: Blister packs of 10, cartons of 30. 20 mg tablets: Blister packs of 10, cartons of 30. 2.5 mg/mL oral solution: 120 mL amber glass bottle with dosing cup.
Contraindications
Hypersensitivity to bilastine or ingredients; history of QT prolongation and/or torsade de pointes, including congenital long QT syndromes.
Warnings and precautions
Associated with QTc interval prolongation; caution in patients at risk of torsade de pointes. May rarely cause drowsiness affecting driving/operating machinery.
What can be used instead?
Other Canadian products sharing ATC code R06AX29 BILASTINE. 10 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-BILASTINE | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02541556 |
| BLEXTEN | 10 MG | TABLET (ORALLY DISINTEGRATING) | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 02519038 |
| BLEXTEN | 20 MG | TABLET | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 02454130 |
| GLN-BILASTINE | 20 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | DIN 02544369 |
| JAMP BILASTINE | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02546795 |
| M-BILASTINE | 20 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02548410 |
| MAR-BILASTINE | 20 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02547279 |
| NRA-BILASTINE | 20 MG | TABLET | NORA PHARMA INC | MARKETED | DIN 02551934 |
| SANDOZ BILASTINE | 20 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02536269 |
Who else supplies BILASTINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BILASTINE appears in 45 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.